Real-world clinical outcomes in patients with multiple myeloma treated with isatuximab after daratumumab treatment

Kikuchi, T; Tsukada, N; Nomura, M; Kasuya, Y; Oda, Y; Sato, K; Takei, T; Ogura, M; Abe, Y; Suzuki, K; Ishida, T

Kikuchi, T (通讯作者)，Japanese Red Cross Med Ctr, Dept Hematol, 4 Chome 1-22 Hiroo,Shibuya Ku, Tokyo 1508935, Japan.

ANNALS OF HEMATOLOGY, 2023; 102 (6): 1477

Abstract

Isatuximab and daratumumab are anti-CD38 monoclonal antibodies used to treat refractory multiple myeloma. Isatuximab is often used after unsuccessful ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索